JR-141 + Idursulfase + JR-141 or Idursulfase
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis II
Conditions
Mucopolysaccharidosis II
Trial Timeline
Feb 14, 2022 → Oct 31, 2027
NCT ID
NCT04573023About JR-141 + Idursulfase + JR-141 or Idursulfase
JR-141 + Idursulfase + JR-141 or Idursulfase is a phase 3 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is active. This product is registered under clinical trial identifier NCT04573023. Target conditions include Mucopolysaccharidosis II.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04573023 | Phase 3 | Active |
Competing Products
20 competing products in Mucopolysaccharidosis II